Market: NASD |
Currency: USD
Address: Fitzwilliam Court
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
📈 Iterum Therapeutics plc Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$7.00
-
Upside/Downside from Analyst Target:
869.53%
-
Broker Call:
4
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
10-25%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2025-11-13
-
EPS Estimate:
-0.21
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2022 |
- |
$0.066667 |
- |
2022-08-18 |
- |
Stock split |
|
Total Amount for 2022: $0.066667 |
📅 Earnings & EPS History for Iterum Therapeutics plc
| Date | Reported EPS |
|---|
| 2025-11-13 (estimated upcoming) | - |
| 2025-08-05 | -0.16 |
| 2025-05-13 | -0.14 |
| 2025-02-07 | -0.12 |
| 2024-11-14 | -0.24 |
| 2024-08-14 | -0.23 |
| 2024-05-13 | -0.38 |
| 2024-03-28 | -0.81 |
| 2023-11-14 | -1.2 |
| 2023-08-11 | -0.77 |
| 2023-05-12 | -0.58 |
| 2023-03-16 | -0.52 |
| 2022-11-10 | -0.43 |
| 2022-08-12 | -0.45 |
| 2022-05-13 | -0.45 |
| 2022-03-28 | -0.3 |
| 2021-11-12 | -0.45 |
| 2021-08-13 | -0.6 |
| 2021-05-14 | -0.75 |
| 2021-03-12 | -1.65 |
| 2020-11-16 | -5.1 |
| 2020-08-06 | -8.4 |
| 2020-05-14 | -13.5 |
| 2020-03-12 | -23.85 |
| 2019-11-12 | -32.25 |
📰 Related News & Research
No related articles found for "iterum therapeutics".
